• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

韩国奥密克戎(BA.1/BA.2)流行期间与 COVID-19 再感染和死亡相关的危险因素。

Risk Factors Related to COVID-19 Reinfection and Fatality During the Omicron (BA.1/BA.2) Period in Korea.

机构信息

Division of Epidemiological Investigation Analysis, Korea Disease Control and Prevention Agency, Cheongju, Korea.

Division of Infectious Disease Control, Korea Disease Control and Prevention Agency, Cheongju, Korea.

出版信息

J Korean Med Sci. 2023 Aug 28;38(34):e269. doi: 10.3346/jkms.2023.38.e269.

DOI:10.3346/jkms.2023.38.e269
PMID:37644683
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10462479/
Abstract

BACKGROUND

This study aimed to investigate the deaths due to coronavirus disease 2019 (COVID-19) reinfection and related risk factors.

METHODS

National cohort data were collected for a six-month period when omicron BA.1/BA.2 variant was dominant in South Korea.

RESULTS

The long-term care facility residents (adjusted odds ratio, 3.11; 95% confidence interval [CI], 2.98-3.25) had significantly higher risk of reinfection than the general population. The risk of reinfection was significantly lower for persons with 2 or more vaccine doses compared to the unvaccinated. The risk of death was significantly higher in the reinfection group than in the primary infection group for persons in the 60-74 years age group (adjusted relative risk [aRR], 1.62; 95% CI, 1.19-2.20), and immunocompromised group (aRR, 4.56; 95% CI, 2.34-8.90).

CONCLUSION

In these data, vaccination history was significantly related to reduced COVID-19 reinfection and severe progression, and scheduled vaccinations were important even with a history of infection.

摘要

背景

本研究旨在调查 2019 年冠状病毒病(COVID-19)再感染导致的死亡病例,并分析相关危险因素。

方法

在韩国奥密克戎 BA.1/BA.2 变异株占主导地位的六个月期间,收集了全国性队列数据。

结果

与普通人群相比,长期护理机构居民(调整后的优势比,3.11;95%置信区间[CI],2.98-3.25)的再感染风险显著更高。与未接种疫苗者相比,接种 2 剂或更多疫苗者的再感染风险显著降低。对于 60-74 岁年龄组(调整后的相对风险[aRR],1.62;95%CI,1.19-2.20)和免疫功能低下组(aRR,4.56;95%CI,2.34-8.90)的患者,再感染组的死亡风险显著高于初次感染组。

结论

在这些数据中,疫苗接种史与降低 COVID-19 再感染和严重病情进展显著相关,即使有感染史,定期接种疫苗也很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2eb3/10462479/ccf4407165ab/jkms-38-e269-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2eb3/10462479/ccf4407165ab/jkms-38-e269-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2eb3/10462479/ccf4407165ab/jkms-38-e269-g001.jpg

相似文献

1
Risk Factors Related to COVID-19 Reinfection and Fatality During the Omicron (BA.1/BA.2) Period in Korea.韩国奥密克戎(BA.1/BA.2)流行期间与 COVID-19 再感染和死亡相关的危险因素。
J Korean Med Sci. 2023 Aug 28;38(34):e269. doi: 10.3346/jkms.2023.38.e269.
2
Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.疫苗对 Alpha、Delta 或奥密克戎变异株流行期间 SARS-CoV-2 再感染的有效性:一项丹麦全国性研究。
PLoS Med. 2022 Nov 22;19(11):e1004037. doi: 10.1371/journal.pmed.1004037. eCollection 2022 Nov.
3
Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022.疫苗接种状态、主要变异株和既往感染后时间对 2020 年 2 月至 2022 年 2 月意大利雷焦艾米利亚省 SARS-CoV-2 再感染风险的影响:一项队列研究。
Euro Surveill. 2023 Mar;28(13). doi: 10.2807/1560-7917.ES.2023.28.13.2200494.
4
Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.2021 年 8 月至 2022 年 3 月,英国青少年在先前感染和接种疫苗后对 delta(B.1.617.2)和 omicron(B.1.1.529)BA.1 和 BA.2 SARS-CoV-2 变异株的症状性感染的保护作用:一项全国性、观察性、基于检测的病例对照研究。
Lancet Infect Dis. 2023 Apr;23(4):435-444. doi: 10.1016/S1473-3099(22)00729-0. Epub 2022 Nov 24.
5
Clinical severity according to the primary infection variant in patients with suspected SARS-CoV-2 reinfection in Korea.韩国疑似 SARS-CoV-2 再感染患者中根据初次感染变异株的临床严重程度。
Epidemiol Health. 2023;45:e2023007. doi: 10.4178/epih.e2023007. Epub 2022 Dec 21.
6
Clinical Characteristics and Risk Factors for Mortality in Critical COVID-19 Patients Aged 50 Years or Younger During Omicron Wave in Korea: Comparison With Patients Older Than 50 Years of Age.韩国奥密克戎变异株流行期间 50 岁及以下危重症 COVID-19 患者的临床特征及死亡危险因素:与 50 岁以上患者的比较。
J Korean Med Sci. 2023 Jul 17;38(28):e217. doi: 10.3346/jkms.2023.38.e217.
7
Reinfection rate and disease severity of the BA.5 Omicron SARS-CoV-2 lineage compared to previously circulating variants of concern in the Canary Islands (Spain).与先前在加那利群岛(西班牙)流行的关注变异株相比,BA.5 奥密克戎 SARS-CoV-2 谱系的再感染率和疾病严重程度。
Emerg Microbes Infect. 2023 Dec;12(1):2202281. doi: 10.1080/22221751.2023.2202281.
8
History of primary-series and booster vaccination and protection against Omicron reinfection.初级系列和加强针接种史与奥密克戎再感染的保护作用。
Sci Adv. 2023 Oct 6;9(40):eadh0761. doi: 10.1126/sciadv.adh0761. Epub 2023 Oct 4.
9
Age-specific Risk of SARS-CoV-2 Reinfection During Omicron Outbreaks, South Korea.奥密克戎变异株流行期间,韩国各年龄段人群再次感染 SARS-CoV-2 的风险。
Pediatr Infect Dis J. 2023 Aug 1;42(8):e296-e297. doi: 10.1097/INF.0000000000003960. Epub 2023 Apr 24.
10
SARS-CoV-2 Reinfections in Health-Care Workers, 1 March 2020-31 January 2023.2020 年 3 月 1 日至 2023 年 1 月 31 日期间医护人员中 SARS-CoV-2 再感染情况。
Viruses. 2023 Jul 14;15(7):1551. doi: 10.3390/v15071551.

引用本文的文献

1
Clinical and immunological insights into SARS-CoV-2 reinfection: a propensity score-matched cohort study.对严重急性呼吸综合征冠状病毒2型再次感染的临床和免疫学见解:一项倾向评分匹配队列研究。
BMC Infect Dis. 2025 Aug 1;25(1):970. doi: 10.1186/s12879-025-11398-0.
2
An online survey among convalescents 5 months post SARS-CoV-2 infection in China.在中国对新冠病毒感染康复者进行的一项5个月后的在线调查。
Biosaf Health. 2024 Jun 13;6(4):206-215. doi: 10.1016/j.bsheal.2024.06.001. eCollection 2024 Aug.
3
Characteristics and risk factors associated with COVID-19 reinfection in Hong Kong: a retrospective cohort study.

本文引用的文献

1
Severity and Outcomes of SARS-CoV-2 Reinfection Compared with Primary Infection: A Systematic Review and Meta-Analysis.与初次感染相比,SARS-CoV-2 再感染的严重程度和结局:系统评价和荟萃分析。
Int J Environ Res Public Health. 2023 Feb 14;20(4):3335. doi: 10.3390/ijerph20043335.
2
Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents.mRNA 新冠病毒疫苗第二剂加强针在免疫功能低下人群和长期护理机构居民中的有效性。
Emerg Infect Dis. 2022 Nov;28(11):2165-2170. doi: 10.3201/eid2811.220918. Epub 2022 Oct 3.
3
SARS-CoV-2 reinfections during the first three major COVID-19 waves in Bulgaria.
香港新冠病毒再感染的特征及相关风险因素:一项回顾性队列研究。
Epidemiol Infect. 2025 Feb 7;153:e30. doi: 10.1017/S0950268825000172.
4
Incidence, severity, risk factors and outcomes of SARS-CoV-2 reinfections during the Omicron period: a systematic review and meta-analysis.奥密克戎时期新型冠状病毒再次感染的发病率、严重程度、风险因素及结局:一项系统评价和荟萃分析
J Glob Health. 2025 Feb 7;15:04032. doi: 10.7189/jogh.15.04032.
5
Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.奥密克戎变异株再感染风险的混合免疫元分析。
Front Public Health. 2024 Aug 26;12:1457266. doi: 10.3389/fpubh.2024.1457266. eCollection 2024.
6
Changes in the intrinsic severity of severe acute respiratory syndrome coronavirus 2 according to the emerging variant: a nationwide study from February 2020 to June 2022, including comparison with vaccinated populations.根据新兴变异株,严重急性呼吸综合征冠状病毒 2 的固有严重程度的变化:一项 2020 年 2 月至 2022 年 6 月的全国性研究,包括与接种疫苗人群的比较。
BMC Infect Dis. 2024 Jan 2;24(1):1. doi: 10.1186/s12879-023-08869-7.
SARS-CoV-2 再感染在保加利亚前三次 COVID-19 大流行期间。
PLoS One. 2022 Sep 9;17(9):e0274509. doi: 10.1371/journal.pone.0274509. eCollection 2022.
4
Effectiveness Associated With Vaccination After COVID-19 Recovery in Preventing Reinfection.新冠康复后接种疫苗在预防再次感染方面的有效性。
JAMA Netw Open. 2022 Jul 1;5(7):e2223917. doi: 10.1001/jamanetworkopen.2022.23917.
5
Reinfection with SARS-CoV-2 in general population, South Korea; nationwide retrospective cohort study.一般人群中 SARS-CoV-2 的再感染,韩国;全国回顾性队列研究。
J Med Virol. 2022 Nov;94(11):5589-5592. doi: 10.1002/jmv.28026. Epub 2022 Aug 2.
6
Effectiveness of a fourth dose of mRNA COVID-19 vaccine against all-cause mortality in long-term care facility residents and in the oldest old: A nationwide, retrospective cohort study in Sweden.第四剂mRNA新冠疫苗对长期护理机构居民和高龄老人全因死亡率的有效性:瑞典一项全国性回顾性队列研究
Lancet Reg Health Eur. 2022 Oct;21:100466. doi: 10.1016/j.lanepe.2022.100466. Epub 2022 Jul 13.
7
Reinfection in patients with COVID-19: a systematic review.COVID-19 患者再感染:系统评价。
Glob Health Res Policy. 2022 Apr 29;7(1):12. doi: 10.1186/s41256-022-00245-3.
8
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.在全国范围内接种第四剂 BNT162b2 mRNA 新冠疫苗。
N Engl J Med. 2022 Apr 28;386(17):1603-1614. doi: 10.1056/NEJMoa2201688. Epub 2022 Apr 13.
9
Impact of the Omicron variant on SARS-CoV-2 reinfections in France, March 2021 to February 2022.2021年3月至2022年2月,奥密克戎变异株对法国新冠病毒再感染情况的影响
Euro Surveill. 2022 Mar;27(13). doi: 10.2807/1560-7917.ES.2022.27.13.2200247.
10
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa.南非出现奥密克戎后,SARS-CoV-2 再感染的风险增加。
Science. 2022 May 6;376(6593):eabn4947. doi: 10.1126/science.abn4947.